http://dx.doi.org/10.3346/jkms.2013.28.7.1107 • *J Korean Med Sci 2013; 28: 1107-1110* 

# Osteogenesis Imperfecta Type VI with Severe Bony Deformities Caused by Novel Compound Heterozygous Mutations in *SERPINF1*

#### Sung Yoon Cho,<sup>1\*</sup> Chang–Seok Ki,<sup>2\*</sup> Young Bae Sohn,<sup>3</sup> Su Jin Kim,<sup>4</sup> Se Hyun Maeng,<sup>1</sup> and Dong–Kyu Jin<sup>1</sup>

Departments of <sup>1</sup>Pediatrics, <sup>2</sup>Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; <sup>3</sup>Department of Medical Genetics, Ajou University Hospital, Suwon; <sup>4</sup>Department of Pediatrics, Myongji Hospital, Kwandong University College of Medicine, Goyang, Korea

\*Sung Yoon Cho and Chang-Seok Ki contributed equally to this work.

Received: 27 November 2012 Accepted: 15 February 2013

Address for Correspondence: Dong-Kyu Jin, MD Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangman-gu, Seoul 135-710, Korea Tel: +82.2-3410-3525, Fax: +82.2-3410-0043 E-mail: jind&@skku.edu

The study was supported by the Korea Healthcare Technology RED Project; Grant sponsor: Ministry for Health, Welfare and Family Affairs, Republic of Korea; Grant number: A080588; Grant sponsor: Samsung Biomedical Research Institute; Grant numbers: C-A9-240-2 Grant sponsor: In-Sung Foundation for Medical Research.

## **INTRODUCTION**

Osteogenesis imperfecta (OI) comprises a heterogeneous group of disorders characterized bone fragility, deformity of the spine and long bones, and other clinical symptoms such as short stature, blue sclera, and dentinogenesis imperfecta (1, 2). Almost all patients have presumed or proven defects in type I (pro)collagen biosynthesis (3). In 1979, David Sillence developed a fourtype classification that is still in use for classifying clinical/radiological features: OI type I (mild OI with bone fragility and blue sclera), II (perinatal lethal), III (progressive deforming), and IV (normal sclera and mild deformity) (4, 5). Dominantly inherited mutations of *COL1A1* or *COL1A2*, which encode collagen type I alpha chains, appear to be causative in the majority of OI types.

In 2004, OI types V and VI were added to this classification because of specific clinical/radiological or typical histological

Osteogenesis imperfecta (OI) comprises a heterogeneous group of disorders characterized by bone fragility, frequent fractures, and low bone mass. Dominantly inherited *COL1A1* or *COL1A2* mutations appear to be causative in the majority of OI types, but rare recessively inherited genes have also been reported. Recently, *SERPINF1* has been reported as another causative gene in OI type VI. To date, only eight *SERPINF1* mutations have been reported and all are homozygous. Our patient showed no abnormalities at birth, frequent fractures, osteopenia, and poor response on pamidronate therapy. At the time of her most recent evaluation, she was 8 yr old, and could not walk independently due to frequent lower-extremity fractures, resulting in severe deformity. No clinical signs were seen of hearing impairment, blue sclera, or dentinogenesis imperfecta. In this study, we describe the clinical and radiological findings of one Korean patient with novel compound heterozygous mutations (c.77dupC and c.421dupC) of *SERPINF1*.

Key Words: Osteogenesis Imperfecta; Osteogenesis Imperfect Type VI; SERPINF1; Pigment Epithelium-derived Factor

features, absence of abnormalities of type I (pro)collagen synthesis, and absence of causative variants *COL1A1* or *COL1A2* (6-8). With the discovery of the rare recessively inherited mutations of OI, an extension of the classification was proposed to include OI types VII and VIII (7). However, the classification and subdivision into different types of OI is still under discussion (3) because the phenotypic spectrum that results from mutations in some of these genes is almost as broad as that seen for mutations in type I collagen genes.

Recessively inherited OI genes have been reported, including *CRTAP, LEPRE1, PPIB, FKBP10, PLOD2, SERPINF1, SERPINH1, BMP1, LRP5*, and *SP7*. Recent research has demonstrated that OI type VI is caused by loss-of-function mutations in *SERPINF1* (9). An earlier report had found inactivating mutations of *SER-PINF1* in severe OI, but the lack of bone histology prevented establishment of a link to OI type VI (10).

#### pISSN 1011-8934 eISSN 1598-6357

JKMS


In the present study, we describe the clinical, radiological, and molecular findings of a Korean patient who presented with a novel compound heterozygous mutation of *SERPINF1*. The patient showed an initially mild and then progressively worsening form of OI, with severe deformities of the long bones.

### **CASE DESCRIPTION**

#### Patient summary

The patient was born after 40 weeks of gestation by spontaneous vaginal delivery. Her birth height was 50 cm (50th percentile), and her birth weight was 3,400 g (50th percentile). No limb deformities or other abnormalities, including joint hyperlaxity or skin hyperelasticity, were noted at birth and both scleras were white. The patient's parents were non-consanguineous and healthy; her only sibling, an older sister, was unaffected. No family history of bone fragility was identified. She was able to sit independently at 9 months and walk independently at 16 months.

At 18 months (2005-05-02), she presented with a nondisplaced fracture in the right proximal femur diaphysis without any traumatic episode (Fig. 1A). At that time, her height was 78.6 cm (10-25th percentile), and her weight was 9.5 kg (3rd percentile). The data from biological tests (i.e., routine blood cell count, blood and urinary levels of calcium, phosphate, creatinine, serum alkaline phosphatase, 25-hydroxyvitamin D, parathyroid hormone, and urine analysis) appeared within normal ranges, while the serum level of the bone resorption marker type



**Fig. 1.** (A) Right femur radiogram taken at the age of 18 months shows a fracture of the proximal metadiaphysis in the right femur. (B) Thorax of the patient at the age of 8 yr shows a somewhat decreased lung volume, generalized vertebral plana with diffuse osteopenia, and progressed thoracic scoliosis. (C) Radiographs of the right and left leg when the patient was 8 yr old show bilateral coxa vara, fractures treated using intramedullary fixation, and "popcorn epiphyses."

I collagen telopeptide was slightly above the normal values. After the first fracture, she frequently experienced nontraumatic fractures. No radiographic signs of rickets were observed. The history of the frequent fractures without apparent injury suggested bone fragility and the radiologic features, including osteopenia, enabled us to diagnose OI. Dual-energy x-ray absorptiometry showed the values of the lumbar vertebrae L1- to-L4 to be very low (0.204 g/cm<sup>2</sup>, T score -7.0) at age 2 yr 10 months. She had received monthly intravenous pamidronate (20 mg per m<sup>2</sup> of body surface area) beginning at the age of 3 yr 1 month, because she had had frequent episodes of fractures. She showed no side effects; however, her growth remained very slow and she continued to have one or more long-bone fractures annually. After 12 cycles of pamidronate, the L1- to-L4 spine areal bone mineral density T-score was -6.1 (0.277 g/cm<sup>2</sup>).

At the time of her most recent evaluation, she was 8 yr old and had been receiving monthly intravenous pamidronate due to intermittent fractures. Growth was severely restricted; therefore, her height at the time of this writing was markedly less than the 3rd percentile (about 100 cm). The girl could not walk independently due to frequent lower-extremity fractures, resulting in severe deformity. She was only able to stand with assistance, and was dependent upon a wheelchair for mobility. No clinical signs were seen of hearing impairment, ophthalmological problems, cardiac murmur, respiratory difficulty, neurologic problems, or dentinogenesis imperfecta. Her intellectual development was normal.

She experienced more than ten fractures in her lifetime until 8 yr of age; six of these fractures required orthopedic surgical procedures. She had severe scoliosis (Fig. 1B), bilateral coxa vara, acetabular protrusion, severe bowing of all long bones, and "popcorn epiphyses" at the age of 8 yr (Fig. 1C).

The heterogeneity of OI hampers genetic diagnosis, particularly in autosomal recessive forms of OI. Given that many genes are involved in OI, and that the *COL1A1* and *COL1A2* genes are difficult to analyze by conventional Sanger sequencing, we performed whole exome sequencing (WES) to identify the muta-




Fig. 2. *SERPINF1* mutations demonstrated by Sanger sequencing. The patient had compound heterozygous mutations (c.77dupC and c.421dupC; arrows) of *SERPINF1*. Her father and mother were confirmed to be heterozygous carriers.

tions in our patient. Blood samples were collected from the patient and her parents after informed consent had been obtained.

#### Mutations in SERPINF1

Detailed methods of exome sequencing and validation of novel variants by Sanger sequencing are shown in the supplementary data. A mean coverage of 100.5X was achieved and 89.2% of the targeted bases were read > 10 times by exome capture and massive parallel sequencing (Supplementary Table 1). We checked the OI-related genes, including *COL1A1, COL1A2, CRTAP, P3H1, FKBP10, LEPRE1, PLOD2, PPIB, SERPINH1,* and *SP7,* covering all exons and their flanking intronic regions, but found no disease-associated mutations in these genes.

We ultimately focused on two deleterious variants, c.77dupC and c.421dupC, of *SERPINF1* as the best candidates for further evaluation. Detailed view of individual sequencing reads is shown in Supplementary Fig. 1. They were validated by Sanger sequencing in the patient and her family members. We identified compound heterozygous insertions in exon 2 (c.77dupC; p.Glu27Glyfs\*38) and in exon 4 (c.421dupC; p.Arg141Profs\*5) of *SERPINF1* in the patient (Fig. 2). The father and mother of the patient were confirmed to be heterozygous carriers of each variant. These variants were not found in 192 control chromosomes.

#### **DISCUSSION**

To date, only eight *SERPINF1* mutations have been reported and are homozygous nonsense or frameshift mutations or in-frame duplications. We report the first compound heterozygous mutations (c.77dupC and c.421dupC) in the *SERPINF1* gene that are associated with OI.

Patients with OI type VI usually do not have fractures or bone deformity at birth, but typically sustain their first fracture after the age of 6 months. Compared to other types of OI, bisphosphonate treatment appears to be less effective at reducing fracture rates in OI type VI (11). This type of OI type differs from other types in that a mineralization defect occurs in bone tissue, which leads to the accumulation of unmineralized osteoids, such as those seen in osteomalacia (8). These characteristic features of OI type VI are readily revealed by bone histology, but OI type VI has no distinguishing radiological signs and the parameters of calcium and phosphorus metabolism are within normal limits. However, because bone biopsy is invasive, we relied on genetic analysis to confirm our diagnosis.

Our patient appeared healthy at birth and did not suffer any fracture until 18 months of age. The absence of dentinogenesis imperfecta, lack of blue sclera, severe progression of the disease, frequent fractures without adequate trauma, markedly short stature, and inability to walk without assistance were symptoms similar to those recently reported for having homozygous mutations in *SERPINF1* (9, 10, 12). We concluded that our patient

has OI type VI, considering her normal condition at birth, frequent fracture history after 18 months of age, poor response to pamidronate treatment, and severe bony deformities.

SERPINF1 encodes PEDF (pigment epithelium-derived factor), a 50kDa secreted glycoprotein of 418 amino acid residues that shows high affinity for collagens of the extracellular matrix as well as multiple and varied biological properties (13-15). The SERPINF1 mutants described so far all display normal synthesis, posttranslational modification, and secretion of type I collagen (12). PEDF is believed to play a role in bone homeostasis as an inhibitor of bone resorption, since it upregulates osteoprotegerin, which inhibits osteoclast maturation (16). Further studies for a role of PEDF in the pathogenesis of OI type VI should be conducted.

In summary, we report novel compound heterozygous *SER-PINF1* mutations in a Korean patient who showed an initially mild and then progressively worsening form OI, with severe deformities of the long bones. Further investigations in other patients with *SERPINF1* mutations are needed. The present study aids in further definition of the peculiar clinical features of this form of OI.

### REFERENCES

- 1. Lee DY, Cho TJ, Choi IH, Chung CY, Yoo WJ, Kim JH, Park YK. *Clinical* and radiological manifestations of osteogenesis imperfecta type V. J Korean Med Sci 2006; 21: 709-14.
- 2. Choi JH, Shin YL, Yoo HW. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. J Korean Med Sci 2007; 22: 209-12.
- Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet 2010; 53: 1-5.
- Byers PH, Krakow D, Nunes ME, Pepin M; American College of Medical Genetics. *Genetic evaluation of suspected osteogenesis imperfecta (OI). Genet Med 2006; 8: 383-8.*
- Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101-16.
- 6. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ. *Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15: 1650-8.*
- 7. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363: 1377-85.
- 8. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17: 30-8.
- 9. Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, et al. *Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res 2011; 26: 2798-803.*
- 10. Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrbach M, Koerber F, Zimmermann K, et al. *Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011; 88: 362-71.*
- 11. Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type

VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 2007; 40: 638-44.

- 12. Venturi G, Gandini A, Monti E, Dalle Carbonare L, Corradi M, Vincenzi M, Valenti MT, Valli M, Pelilli E, Boner A, et al. Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor, causes progressively deforming osteogenesis imperfecta with normal type I collagen. J Bone Miner Res 2012; 27: 723-8.
- 13. Quan GM, Ojaimi J, Li Y, Kartsogiannis V, Zhou H, Choong PF. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif

Tissue Int 2005; 76: 146-53.

- 14. Tombran-Tink J. PEDF in angiogenic eye diseases. Curr Mol Med 2010; 10: 267-78.
- 15. Meyer C, Notari L, Becerra SP. *Mapping the type I collagen-binding site* on pigment epithelium-derived factor: implications for its antiangiogenic activity. J Biol Chem 2002; 277: 45400-7.
- Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong PF. PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Biophys Res Commun 2010; 391: 789-94.

#### Supplementary data

#### Supplementary Table 1. Exome Sequencing Statistics

#### **Exome Sequencing**

With parental informed consent, genomic DNA (gDNA) was extracted from peripheral blood leukocytes using the Wizard Genomic DNA purification kit according to the manufacturer's instructions (Promega, Madison, WI, USA), and subjected to exome capture by using TruSeq Exome Enrichment kit (Illumina, San Diego, CA, USA). For captured library construction, one microgram of gDNA was fragmented by nebulization, and Illumina adapters were then ligated to the fragments. A 350–400 base pair product was selected and amplified by polymerase chain reaction (PCR). The final product was validated using the Agilent Bioanalyzer (Santa Clara, CA, USA). The pooled DNA libraries were mixed with capture probes of targeted regions and subjected to three cycles of hybridization-elution steps for library enrichment.

For clustering and sequencing of DNA library, a flow cell containing millions of unique clusters was loaded into the HiSeq 2000 (Illumina, San Diego, CA, USA) for automated cycles of extension and imaging. Paired-end sequences produced by HiSeq2000 were mapped to the human genome, where the reference sequence was UCSC assembly hg19 (NCBI build 37), without unordered sequences or alternate haplotypes, using the mapping program BWA (version 0.5.9rc1). Uniquely mapped reads were only included for the latter steps. After making a consensus sequence by creating a pileup file from BAM file, variant calling process was run using SAMtools (version 0.1.12a), at which stage SNP and short indels candidates were detected at nucleotide resolution. Then those variants were annotated by ANNOVAR (version 2011 Jun 18) to filter SNPs from dbSNP for the version of 131 and 132, and SNPs from the 1000-genomes project (http://1000genomes.org).

#### **Sanger Sequencing**

SERPINF1 exons and their flanking introns were amplified using primer sets designed by the authors (available upon request). The PCR was performed with a thermal cycler (Verti, Applied Biosystems, Foster City, CA) as follows: 32 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 30 sec. After treatment of the amplicon  $(5 \mu L)$  with 10 U shrimp alkaline phosphatase and 2 U exonuclease I (USB Corp., Cleveland, OH), direct sequencing was performed with the BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) on the ABI Prism 3730xl genetic analyzer (Applied Biosystems). To describe sequence variations, we followed the guidelines from the Human Genome Nomenclature Committee (HGVS); so "A" of the ATG translation start site was numbered +1 for DNA sequence and the first methionine was numbered +1 for protein sequence.



#### Supplementary Fig. 1A



